Conditional Approval for Important New Drug

Varenzin-CA1 helps control potentially fatal anemia in cats with CKD

The Food and Drug Administration (FDA) conditionally approved Varenzin-CA1 (molidustat oral suspension) for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats. Nonregenerative anemia can be fatal because the cat’s bone marrow can’t produce enough red blood cells to replace the dead ones removed from the blood. This inhibits oxygen from being carried from the lungs throughout the body.

To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to CatWatch

Get the next year of CatWatch for just $20. And access all of our back issues and online content free of charge.
Subscribe today and save 50% off the regular rate!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access